#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hepatic angiosarcoma Hereditary haemorrhagic telangiectasia Penile squamous cell carcinoma Dermatomyositis Chondrosarcoma metastatic Ehlers-Danlos syndrome Primary biliary cholangitis Oesophageal adenocarcinoma stage II Factor VIII deficiency Meningococcal immunisation Spina bifida Dementia Ventricular tachycardia Neuroendocrine carcinoma of the skin Synovial sarcoma metastatic More trials…

    Learn about Rare Diseases

    Immunodeficiency congenital SAPHO syndrome – Trials in Disease Haemolytic uraemic syndrome – Basic Information Haemophilia B with anti factor IX – Diagnostics Adrenogenital syndrome – Life with Disease Primary mediastinal large B-cell lymphoma – Life with Disease Von Willebrand’s disease – Diagnostics Idiopathic inflammatory myopathy – Trials in Disease Hepatic angiosarcoma Acute respiratory distress syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Telitacicept Pilocarpine Nitrate SOVATELTIDE RLY-2608 Rucaparib Doxorubicin Hydrochloride Bupropion Hydrochloride Naproxen PETHIDINE HYDROCHLORIDE VG801-1 Casirivimab Raludotatug Deruxtecan Aon-D21 Irinotecan Hydrochloride Deucravacitinib Sparsentan FRUQUINTINIB Fluoroethyltyrosine F-18 Calcium Chloride Dihydrate Omp65 More therapies…

    Learn about Your Condition

    Myeloproliferative neoplasm Metastatic malignant melanoma Transferrin decreased Systemic scleroderma Metastases to meninges Vulvovaginal dryness Polymyositis Device related infection Dyspepsia Loeys-Dietz syndrome Malformation venous Autoimmune disorder Triple positive breast cancer Infertility male Acquired ATTR amyloidosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Triple negative breast cancer

  • Study on the Effects and Safety of PLX038 for Patients with Advanced or Metastatic Triple-Negative Breast Cancer

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Peg-7-Ethyl-10-Hydroxycamptothecin
    France

  • Study on Triple Negative Breast Cancer Treatment with Chemotherapy, Fasting-Mimicking Diet, and Metformin for Preoperative Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Metformin Hydrochloride
    Italy

  • Study on Imaging with 89Zr-Atezolizumab to Monitor Immune Responses in Patients with Metastatic Triple Negative Breast Cancer Using Atezolizumab and Drug Combination

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Triple negative breast cancer
    Investigated Drugs:
    • Atezolizumab
    • Carboplatin
    • Paclitaxel Albumin-Bound
    Sweden

  • Study of Pembrolizumab and Chemotherapy for Patients with Triple Negative Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Anhydrous Cyclophosphamide
    • Filgrastim
    • Glatiramer Acetate
    France Germany Ireland Italy Poland Portugal +2

  • Study on the Safety and Effectiveness of Sacituzumab Govitecan for Patients with Triple Negative Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    Belgium France

  • Study on Tiragolumab, Atezolizumab, and Chemotherapy for Patients with Early and Metastatic Triple Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    • Atezolizumab
    • Carboplatin
    France
Previous Page
1 … 9 10 11 12
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!